Antithrombin III Infusion in Patients Undergoing Peritoneovenous Shunt Operation: Failure in the Prevention of Disseminated Intravascular Coagulation

Summary

Five patients with chronic liver disease and acquired antithrombin III (AT III) deficiency undergoing peritoneovenous (LeVeen) shunting for ascites, resistant to medical therapy, were studied prospectively for the development of disseminated intravascular coagulation (D.I.C.) after selective correction of the plasma AT III activity. This was accomplished by continuous infusion of purified human AT III concentrate beginning one day prior to surgery and continuing five to seven days post-operatively. This rigorous transfusion scheme of AT III concentrate could not prevent D.I.C. and bleeding.

Keywords

Antithrombin III concentrate - DIC - Le Veen Shunt - Liver cirrhosis

• References

• 1 Berkowitz HD, Mullen JL, Miller LD. et al. Improved renal function and inhibition of renin and aldosterone secretion following peritoneovenous (LeVeen) shunt. Surgery 1978; 84: 120-126
• 2 Biggs R. Human blood coagulation, haemostasis and thrombosis. Oxford: Blackwell Scientific Publications; 1972
• 3 Brand P, Jespersen J, Gregersen G. Post partum haemolytic-uraemic syndrome successfully treated with Antithrombin III. Br Med J 1980; 1: 449-450
• 4 Büller HR, Weenink AH, Treffers PE, Kahlé LH, Otten HA, Ten CateJW. Severe antithrombin III deficiency in a patient with preeclampsia. Observations on the effect of human AT III concentrate transfusion. Scand J Haematol 1980; 25: 81
• 5 Collen D, Rouvier J, Chamone DAF, Verstraete M. Turnover of radiolabelled plasminogen and prothrombin in cirrhosis of the liver. Eur J Clin Invest 1978; 8: 185-195
• 6 Fumarola D. Intravascular coagulation ascitic fluid infusion and endotoxin. Ann Int Med 1979; 91: 929
• 7 Giles AR, Sauder D, Seaton TL, Johnston M, Hirsh J. Changes in the coagulation status of patients undergoing autotransfusion of concentrated ascitic fluid as treatment of refractory ascites. Blood 1977; 50: 577
• 8 Godal HC, Abildgaard U. Gelation of soluble fibrin in plasma ethanol. Scand J Haematol 1966; 3: 342-350
• 9 Harmon DC, Demirjian Z, Ellman L, Fisher JE. Disseminated intravascular coagulation with the peritoneovenous shunt. Ann Int Med 1979; 90: 774-776
• 10 Kahlé LH, Schipper HG, Jenkins CSP, Ten CateJW. An automated method for the determination of antithrombin III activity. Thromb Res 1978; 12: 1003-1014
• 11 Kahlé LH, Lamping RJ, Ten CateJW. An automated amidolytic method for determination of plasminogen activity. In: Proceedings Second Amstol symposium. Amsterdam: 1981. p. 102
• 12 Kahlé LH, Lamping RJ, Ten CateJW. Evaluation of an automated amidolytic antiplasmin assay. Thromb Haemostas 1979; 42: 49 (Abstr.).
• 13 Lerner RG, Nelson JC, Corines P. Intravascular coagulation complicating peritoneal-atrial shunts. Abstract. Blood 1975; 50: 274
• 14 Lerner RG, Nelson JC, Corines P, del GuercioL R M. Disseminated intravascular coagulation, complication of LeVeen peritoneovenous shunts. JAMA 1978; 240: 2064-2066
• 15 LeVeen HH, Christoudias G, Moon JP, Luft R, Falk G, Grosberg S. Peritoneovenous shunting for ascites. Ann Surg 1974; 180: 580-591
• 16 LeVeen HH, Wapnick S, Grosberg S, Kinney MJ. Further experience with peritoneovenous shunt for ascites. Ann Surg 1976; 184: 574-581
• 17 Miletich JP, Majerus DW, Majerus PW. Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets. J Clin Invest 1978; 62: 824-831
• 18 Mortenson RA, Lawton RL. Surgical treatment for intractable ascites. Am J Surg 1978; 116: 929-932
• 19 Phillips LL, Rodgers JB. Procoagulant activity of ascitic fluid in hepatic cirrhosis: In vivo and in vitro. Surgery 1979; 86: 714-721
• 20 Schipper HG, Ten CateJW. Antithrombin III transfusion in patients with liver cirrhosis. Br J Haematol 1982; 52: 25-33
• 21 Schipper HG, Kahlé LH, Jenkins CSP, Ten CateJW. Antithrombin III transfusion in disseminated intravascular coagulation. Lancet 1978; 1: 854-856
• 22 Schwartz ML, Swaim WR, Vogel SB. Coagulopathy following peritoneovenous shunting. Surgery 1979; 85: 671-676
• 23 Semeraro N, Fumarola D, Mertens F, Vermylen J. Evidence that endotoxins enhance the factor X activity of washed human platelets. Br J Haematol 1978; 38: 243-249
• 24 Tarao K, So K, Moroi T. et al. Detection of endotoxin in plasma and ascitic fluid of patients with cirrhosis: its clinical significance. Gastroenterology 1977; 73: 539-542
• 25 Thomson J. Hereditary coagulation disorders, laboratory techniques. In: Thomson J. (ed). Blood coagulation and haemostasis. pp. 117-157 Edinburgh, New York, Churchill Livingstone: 1980
• 26 Tytgat GN, Collen D, Verstraete M. Metabolism of fibrinogen in cirrhosis of the liver. J Clin Invest 1971; 50: 1690-1701
• 27 Van WijkEM, Kahlé LH, Ten CateJW. The determination of prothrombin using an automated amidolytic technique. Presented at XVII Congress of the international society of haematology, XV Congress of the international society of blood transfusion. Paris 1978; 2: 862
• 28 Van WijkEM, Kahlé LH, Ten CateJW. Automated amidolytic technique for the determination of factor X and factor X antigen; application to patients. Clin Chem 1980; 1: 885-890